Recently, the carboplatin/paclitaxel/trastuzumab regimen for HER2-positive carcinosarcoma changed from category 2B to category 2A for primary or adjuvant therapy and first-line therapy in the 2/2024 updated version. Here, ERBB2 is linked to carcinosarcoma.